Download the PDF version here - Indo-American Chamber Of ...
Download the PDF version here - Indo-American Chamber Of ...
Download the PDF version here - Indo-American Chamber Of ...
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
solution leverages IBM’s Intelligent Building Management (IIBM) system (a combination of monitoring,<br />
asset management and advanced analytics) along with Ingersoll Rand’s Energy optimization<br />
technologies, to help trigger preventive and predictive maintenance to create smarter buildings,<br />
according to an IBM statement.<br />
Buildings in India account for 30 per cent of energy consumption. <strong>Of</strong> this consumption, <strong>the</strong> major usage<br />
is due to HVAC (heating, ventilating and air-conditioning) and lighting. As <strong>the</strong> Indian economy develops<br />
and commercial infrastructure gets built, it becomes essential to drive robust initiatives to improve<br />
energy efficiency and sustainability. In <strong>the</strong> current economic scenario, with rising energy costs,<br />
organizations are facing capital and operating budget challenges. Maximizing capital productivity<br />
requires increasing asset utilization, efficiency and uptime. Similarly, <strong>the</strong> operating costs of energy and<br />
maintenance need to be optimized, IBM said.<br />
Mr. Venkatesh Valluri, Chairman & President, Ingersoll Rand India said, “Ingersoll Rand has been at <strong>the</strong><br />
forefront of driving ‘Innovation and Technology Convergence’ and to us this means bringing toge<strong>the</strong>r<br />
organizations and technologies on a common platform and converging <strong>the</strong>m to drive profitable<br />
sustainability practices. This partnership is a strategic initiative w<strong>here</strong> IBM and Ingersoll Rand are<br />
combining <strong>the</strong>ir strengths in operations and management systems to bring end-to-end managed<br />
services to customers.” “This partnership with Ingersoll Rand reaffirms our commitment by using<br />
intelligent data to build smarter buildings that are accountable for energy and carbon resource use,<br />
helping create a sustainable environment,” said Mr. Nipun Mehrotra, Vice-President & General<br />
Manager, Sales & Business Development, IBM India/South Asia.<br />
Click <strong>here</strong> for index<br />
Microsoft partners Morpheus, Accel to help startups in India<br />
Software giant Microsoft has partnered with Morpheus and Accel in <strong>the</strong> country to provide support and<br />
services to startup companies, helping <strong>the</strong>m grow <strong>the</strong>ir business.<br />
BizSpark Plus, an extension of <strong>the</strong> earlier BizSpark program, works through incubators and accelerators<br />
to provide value added products and services to high potential startups.<br />
Morpheus and Accel have been appointed accelerators in India, and working through <strong>the</strong>m, <strong>the</strong> program<br />
will offer each of <strong>the</strong>ir startups up to USD 60,000 of Windows Azure services over a 24-month period to<br />
help develop <strong>the</strong>ir ideas and solutions.<br />
Click <strong>here</strong> for index<br />
Indian drug companies, hit US jackpot in December quarter<br />
Five of India’s top 10 pharma firms collectively raked in <strong>the</strong>ir best quarterly revenues in <strong>the</strong> US in<br />
October-December. During this period, total US earnings of Ranbaxy Labs, Dr. Reddy’s, Sun Pharma,<br />
Lupin and Zydus Cadila almost touched Rs. 5,000 crore. This is 80% of what Ranbaxy, Dr. Reddy’s, Lupin<br />
and Cadila cumulatively earn from <strong>the</strong>ir domestic business every year.<br />
Excluding Lupin, which operates in both patented and generic drugs business in <strong>the</strong> US, combined<br />
quarterly earnings of <strong>the</strong> four firms, grew 112% during <strong>the</strong> quarter on an annual basis. The timing, when<br />
several blockbuster drugs with market size over $1billion were losing patent protection, proved<br />
fortunate for many of <strong>the</strong>se firms. The surge in US business comes at a time when many of <strong>the</strong>se<br />
companies feel “irrational” price controls and emerging patent regime are undermining <strong>the</strong>ir growth<br />
potential within <strong>the</strong> country.